세계의 로타바이러스 백신 시장 규모 : 유형별, 최종사용자별, 지역별 범위 및 예측

Global Rotavirus Vaccine Market Size By Type (Rotarix, Rotavac, RotaTeq), By End-user (Hospitals, Clinics, Academic And Research Institutions), By Geographic Scope And Forecast

US $ 3,950 ￦ 5,457,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,701,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,431,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

로타바이러스 백신 시장 규모 및 전망

로타바이러스 백신 시장 규모는 최근 몇 년 동안 빠른 속도로 성장하고 있으며, 2026년부터 2032년까지 CAGR 11.5%로 성장할 것으로 예상됩니다.

• 로타바이러스 백신은 로타바이러스 감염, 특히 신생아 및 영유아의 심각한 설사 및 탈수증의 주요 원인인 로타바이러스 감염을 예방하기 위한 예방책입니다.
• 백신 접종은 면역체계를 자극해 로타바이러스에 대한 항체를 생성하고, 바이러스에 대한 방어력을 높여 감염 시 증상의 심각성을 낮춥니다.
• 로타바이러스는 전염성이 매우 강해 어린이집이나 보육시설에서는 감염이 빠르게 확산됩니다. 예방접종은 보통 액체 또는 정맥주사로 경구 투여합니다. 전 세계적으로 로타바이러스와 관련된 입원 및 사망자 수를 크게 줄일 수 있기 때문에 그 용도는 매우 다양합니다.
• 또한, 로타바이러스 예방접종이 확산되면 질병으로 인한 의료비 및 생산성 저하에 따른 경제적 부담을 줄일 수 있습니다.

로타바이러스 백신 세계 시장 역학

로타바이러스 백신 시장을 형성하는 주요 시장 역학은 다음과 같습니다:

주요 시장 촉진요인:

• 로타바이러스 백신은 로타바이러스 감염, 특히 신생아 및 영유아의 심각한 설사 및 탈수증의 주요 원인인 로타바이러스 감염을 예방하기 위한 예방책입니다.
• 백신 접종은 면역체계를 자극해 로타바이러스에 대한 항체를 생성하고 바이러스에 대한 방어력을 높여 감염 시 증상의 심각성을 낮춥니다.
• 로타바이러스는 전염성이 매우 강해 어린이집이나 보육시설에서는 감염이 빠르게 확산됩니다. 예방접종은 보통 액체 또는 정맥주사로 경구 투여합니다. 전 세계적으로 로타바이러스와 관련된 입원 및 사망자 수를 크게 줄일 수 있기 때문에 그 용도는 매우 다양합니다.
• 또한, 로타바이러스 예방접종이 확산되면 질병으로 인한 의료비 및 생산성 저하에 따른 경제적 부담을 줄일 수 있습니다.
• 로타바이러스 감염의 세계적 부담 : 로타바이러스는 전 세계 신생아 및 영유아의 중증 설사를 유발하는 주요 원인입니다. 로타바이러스 감염은 높은 이환율과 사망률로 인해 효과적인 예방접종 프로그램에 대한 시장 수요가 증가하고 있습니다.
• 정부의 노력과 예방접종 프로그램 : 많은 정부가 국제보건기구와 함께 국가 예방접종 요법의 일환으로 로타바이러스 백신을 적극적으로 장려하고 있습니다. 이러한 지원에는 자금 지원, 인식 개선 캠페인, 공중 보건 프로그램에의 통합 등이 포함되며, 이는 백신 접종 보급과 시장 성장에 큰 도움이 될 수 있습니다.
• 백신 개발의 발전 : 지속적인 연구 개발 노력의 결과, 더 높은 혈청형 커버리지와 효능을 가진 더 새롭고 효과적인 로타바이러스 백신이 출시되고 있습니다. 이러한 기술 혁신은 백신 접종의 수용과 보급을 개선하고 시장 성장을 가속화할 것입니다.
• 의료 인프라 및 인식 개선 : 전 세계 의료 인프라, 특히 개발도상국의 인프라가 개선됨에 따라 예방접종 서비스가 더욱 광범위하게 제공되고 있습니다. 또한 로타바이러스 백신의 이점에 대한 일반 대중의 인식이 높아지면서 시장 성장을 촉진하고 있습니다.

주요 과제

• 콜드체인 물류 및 보관 : 로타바이러스 백신은 유효성을 유지하기 위해 지속적인 냉장 보관이 필요하며, 콜드체인 인프라가 제한된 지역에서는 큰 문제가 됩니다. 이러한 제약은 특히 자원이 부족한 환경에서 백신에 대한 접근성을 떨어뜨리고 폐기율을 높입니다.
• 높은 비용과 접근성 : 로타바이러스 예방접종은 특히 중저소득 국가에서 매우 비싸서 보급에 어려움을 겪고 있습니다. 저렴한 가격으로 예방접종을 받을 수 있는 제약으로 인해 국가 및 개인 예방접종 프로그램이나 의료 계획에 포함되지 못해 시장 확대가 제한되고 있습니다.
• 다른 보건의료 우선순위와의 경쟁 : 로타바이러스 백신은 많은 지역, 특히 보건의료 자원이 부족한 지역에서는 다른 필수적인 보건 조치보다 우선순위가 낮습니다. 이러한 경쟁은 로타바이러스 백신 프로그램의 도입과 확장을 지연시키고 시장 침투를 제한하고 있습니다.

주요 동향

• 새로운 백신 후보 개발 : 더 강력한 효능, 더 우수한 안전성 프로파일, 더 광범위한 균주를 커버하는 새로운 로타바이러스 백신의 개발 추세가 두드러지고 있습니다. 이러한 발전은 현재 백신의 한계를 해결하는 동시에 다양한 인구집단의 미충족 수요를 충족시키기 위해 노력하고 있습니다.
• 중저소득 국가에 대한 관심 증가 : 국제보건기구와 백신 제조업체들은 로타바이러스 질병이 가장 많이 발생하는 중저소득 국가에서 로타바이러스 백신에 대한 접근성을 높이는 데 더욱 집중하고 있습니다. 가격 협상, 현지 제조사와의 제휴, 예방접종 프로그램 자금 지원 등이 그 노력의 일환입니다.
• 국가 예방접종 프로그램과의 통합 : 로타바이러스 백신은 전 세계적으로 예방접종 프로그램에 통합되고 있습니다. 이러한 통합은 로타바이러스 백신 접종이 질병 부담 감소에 효과적이라는 증거가 확산되면서 각국 정부가 로타바이러스 백신을 일상적인 소아 의료에 포함시키려는 움직임이 확산되고 있는 데 따른 것입니다.

목차

제1장 로타바이러스 백신 세계 시장 소개

• 시장 개요
• 조사 범위
• 가정

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH 조사 방법

• 데이터 마이닝
• 검증
• 1차 자료
• 데이터 소스 리스트

제4장 로타바이러스 백신 세계 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델

제5장 로타바이러스 백신 세계 시장 : 유형별

• 개요
• 로타릭스
• 로타백
• 로타텍
• 기타

제6장 로타바이러스 백신 세계 시장 : 최종사용자별

• 개요
• 병원
• 진료소
• 학술·조사
• 기타

제7장 로타바이러스 백신 세계 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 세계 기타 지역
  • 라틴아메리카
  • 중동 및 아프리카

제8장 로타바이러스 백신 세계 시장 경쟁 구도

• 개요
• 각사의 시장 순위
• 주요 개발 전략

제9장 기업 개요

• Merck & Co.
• GlaxoSmithKline plc.
• Beijing Wantai Biological Pharmacy Enterprise Co.
• Walvax Biotechnology Co.
• Bharat Biotech International Limited
• Institute of Vaccines and Medical Biologicals
• Serum Institute of India Pvt. Ltd.
• Chengdu Institute of Biological Products Co
• Incheon Vaccines Ltd
• Deyuan Biotech Group Co.

제10장 주요 발전

• 제품 출시/개발
• 인수합병
• 사업 확대
• 파트너십과 제휴

제11장 부록

• 관련 조사

ksm

영문 목차

영문목차

Rotavirus Vaccine Market Size And Forecast

The Rotavirus Vaccine Market size is growing at a good pace over the last few years and is expected to grow at a CAGR of 11.5% from 2026 to 2032.

• The rotavirus vaccine is a preventive measure intended to combat rotavirus infection, a leading cause of severe diarrhea and dehydration, particularly in newborns and young children.
• The vaccination stimulates the immune system to develop antibodies against rotavirus, giving protection against the virus and decreasing the severity of symptoms if infected.
• Rotavirus is very contagious and spreads quickly in daycare centers and nurseries. The vaccination is usually given orally, either as a liquid or as oral drops, which makes it convenient for newborns. Its applications are numerous, as it greatly reduces the number of rotavirus-related hospitalizations and fatalities globally.
• Furthermore, widespread rotavirus immunization can reduce the economic burden associated with medical expenses and missed productivity due to illness.

Global Rotavirus Vaccine Market Dynamics

The key market dynamics that are shaping the Rotavirus Vaccine Market include:

Key Market Drivers:

• The rotavirus vaccine is a preventive measure intended to combat rotavirus infection, a leading cause of severe diarrhea and dehydration, particularly in newborns and young children.
• The vaccination stimulates the immune system to develop antibodies against rotavirus, giving protection against the virus and decreasing the severity of symptoms if infected.
• Rotavirus is very contagious and spreads quickly in daycare centers and nurseries. The vaccination is usually given orally, either as a liquid or as oral drops, which makes it convenient for newborns. Its applications are numerous, as it greatly reduces the number of rotavirus-related hospitalizations and fatalities globally.
• Furthermore, widespread rotavirus immunization can reduce the economic burden associated with medical expenses and missed productivity due to illness.
• Global Burden of Rotavirus Infections: Rotavirus is a major cause of severe diarrhea in newborns and young children worldwide. Rotavirus infections have a high incidence rate, as well as significant morbidity and mortality, which drives market demand for effective immunization programs.
• Government Initiatives and Immunization Programs: Many governments, along with international health organizations, are aggressively promoting rotavirus vaccines as part of their national immunization regimens. This support includes funding, awareness campaigns, and inclusion in public health programs, which will dramatically increase vaccination adoption and market growth.
• Advancements in Vaccine Development: Continuous research and development efforts have resulted in the launch of newer, more effective rotavirus vaccines with greater serotype coverage and efficacy. These innovations improve vaccination acceptance and adoption, accelerating market growth.
• Increasing Healthcare Infrastructure and Awareness: Immunization services are becoming more widely accessible as the world's healthcare infrastructure, especially in developing nations, gets better. In addition, increasing public awareness of the benefits of rotavirus vaccine stimulates market growth.

Key Challenges:

• Cold Chain Logistics and Storage: Rotavirus vaccines require continual refrigeration to retain efficacy, which presents a substantial issue in areas with limited cold chain infrastructure. This constraint reduces vaccine accessibility and raises waste rates, especially in low-resource settings.
• High Costs and Affordability: Rotavirus vaccinations are prohibitively expensive, particularly in low- and middle-income countries, making widespread adoption challenging. Affordability constraints limit governments' and individuals' abilities to include these vaccinations in national immunization programs or personal healthcare plans, limiting market expansion.
• Competition with Other Healthcare Priorities: The Rotavirus vaccine is not prioritized over other essential health measures in many locations, particularly in areas with little healthcare resources. This competition for resources and attention slows the introduction and expansion of rotavirus vaccine programs, limiting market penetration.

Key Trends:

• Development of New Vaccine Candidates: There is a significant trend toward the development of novel rotavirus vaccines with stronger efficacy, better safety profiles, and broader strain coverage. These advancements attempt to solve current vaccine limitations while also meeting unmet requirements in a variety of populations.
• Growing Focus on Low- and Middle-Income Countries: International health organizations and vaccine producers are focusing more on boosting access to rotavirus vaccines in low- and middle-income countries, where rotavirus disease is most prevalent. Price negotiations, local manufacturing partnerships, and immunization program funding are among the efforts being made.
• Integration with National Immunization Programs: Rotavirus vaccine is increasingly being integrated into national immunization programs around the world. This integration is aided by expanding evidence of the vaccination's effectiveness in reducing disease burden, which encourages governments to incorporate the vaccine into routine pediatric care.

Global Rotavirus Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the Rotavirus Vaccine Market:

North America:

• According to VMR Analyst, North America is estimated to dominate the Rotavirus Vaccine Market during the forecast period. North America, particularly the United States, has a well-established healthcare infrastructure. This allows for widespread vaccine distribution and delivery, ensuring high immunization coverage and boosting market growth in this region.
• Rotavirus vaccine is actively supported by government health agencies in North America, which provide advice, financing, and inclusion in national immunization programs. These measures increase vaccine adoption, which contributes greatly to market domination.
• North Americans benefit from high levels of health awareness and education, which increases acceptance and demand for immunizations such as the rotavirus vaccine. Public health campaigns increase awareness and adoption.
• Furthermore, North America is home to numerous significant vaccine producers and research organizations that specialize in the development and production of rotavirus vaccines. The region's ability to innovate and produce underpins its dominant position in the global market.

Europe:

• European countries have well-established, comprehensive immunization regimens that include rotavirus vaccines as part of the baby vaccination schedule. This government funding assures high immunization coverage and promotes regional market growth.
• Europe has a high level of healthcare investment, which includes public health measures focused on the prevention of infectious diseases. The investment in healthcare infrastructure and preventive measures contributes to the widespread use of rotavirus vaccines.
• European governments commonly work with international health organizations on vaccine procurement and distribution techniques, which aids in overcoming affordability and accessibility issues. These collaborations help to expand the implementation of immunization programs.
• Furthermore, there is a great emphasis on public health education and awareness in Europe, which has resulted in higher vaccine acceptance rates among the general people. Educational efforts promoting the benefits of rotavirus vaccination boost demand and drive market expansion in the region.

Asia Pacific:

• The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. Asia Pacific has a high incidence of rotavirus infections, necessitating an urgent need for effective vaccinations. The high incidence of rotavirus-related illness and mortality among children in this region emphasizes the crucial need for extensive immunization campaigns.
• Many countries in the Asia Pacific region are rapidly improving their healthcare infrastructure, increasing access to vaccines. Increased healthcare investments and immunization program expansion make it easier to distribute and administer rotavirus vaccines, hence driving market growth.
• Rotavirus vaccination is becoming increasingly important in national immunization programs across the Asia Pacific. These programs, which are frequently funded by international health organizations, increase vaccine uptake and promote significant market growth.
• Furthermore, Populations throughout the Asia Pacific are becoming more aware of the value of vaccination in preventing infectious diseases such as rotavirus. This greater awareness, combined with educational initiatives, drives demand for rotavirus vaccines, resulting in market growth.

Global Rotavirus Vaccine Market: Segmentation Analysis

The Global Rotavirus Vaccine Market is segmented based on Type, End-User, And Geography.

Rotavirus Vaccine Market, By Type

• Rotarix
• Rotavac
• RotaTeq
• Others

Based on Type, the market is segmented into Rotarix, Rotavac, RotaTeq, and Others. The RotaTeq segment is estimated to dominate the Rotavirus Vaccine Market due to its widespread acceptance and use in many countries, its efficacy in avoiding rotavirus gastroenteritis caused by the most frequent strains, and its inclusion in national immunization programs. Furthermore, its pentavalent formulation, which covers five rotavirus strains, provides broad protection, leading to its widespread use. Comprehensive safety and efficacy evidence, lengthy clinical trials, and recommendations from health authorities around the world all help to strengthen the vaccine's adoption.

Rotavirus Vaccine Market, By End-User

• Hospitals
• Clinics
• Academics and Research Institutions
• Others

Based on End-User, the market is segmented into Hospitals, Clinics, Academics and Research Institutions, and Others. The hospitals segment is estimated to hold the majority share in the forecast period of the Rotavirus Vaccine Market. Hospitals are primary healthcare venues where immunizations are provided, particularly to infants and young children, who receive the majority of rotavirus vaccines. The centralized nature of hospital facilities facilitates vaccine distribution and delivery, allowing a large number of people to be vaccinated in a controlled and medically monitored environment. Furthermore, hospitals frequently act as crucial centers of education for new parents about the need for vaccination, providing them with the information and resources they need to protect their children from rotavirus infection.

Key Players

• The "Rotavirus Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co., GlaxoSmithKline plc, Walvax Biotechnology Co., Bharat Biotech International Limited, Institute of Vaccines and Medical Biologicals, Serum Institute of India Pvt. Ltd., Chengdu Institute of Biological Products Co., Beijing Wantai Biological Pharmacy Enterprise Co., Incheon Vaccines Ltd, Deyuan Biotech Group Co., Sanyou Biopharmaceuticals Co., Jilin Akeso Biopharmaceutical Co., CanSino Biologics Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi Pasteur and Pfizer Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Rotavirus Vaccine Market Recent Developments
• In November 2023, Medical Xpress reported a study finding that infants exposed to certain biologics during pregnancy can safely receive a rotavirus vaccine.
• In January 2020, The Press Trust of India reported that the Serum Institute launched a new rotavirus vaccine in India, aiming to be a super-cheap option to combat childhood diarrhea.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ROTAVIRUS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ROTAVIRUS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL ROTAVIRUS VACCINE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Rotarix
• 5.3 Rotavac
• 5.4 RotaTeq
• 5.5 Others

6 GLOBAL ROTAVIRUS VACCINE MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Academic and Research
• 6.5 Others

7 GLOBAL ROTAVIRUS VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL ROTAVIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merck & Co.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 GlaxoSmithKline plc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Beijing Wantai Biological Pharmacy Enterprise Co.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Walvax Biotechnology Co.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Bharat Biotech International Limited
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Institute of Vaccines and Medical Biologicals
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Serum Institute of India Pvt. Ltd.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Chengdu Institute of Biological Products Co
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Incheon Vaccines Ltd
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Deyuan Biotech Group Co.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 APPENDIX

• 11.1 Related Research

관련자료